Recursion Reports Grant of Inducement Awards as Permitted by the Nasdaq Listing Rules

Recursion (NASDAQ: RXRX), a prominent clinical-stage TechBio company, recently announced the granting of inducement restricted stock unit (RSU) awards as part of its strategic initiatives to attract new talent. On February 6, 2026, the Compensation Committee of Recursion's Board of Directors approved awards covering a total of 820,431 shares of Class A common stock, allocated to 17 new employees. This initiative falls under Recursion's 2024 Inducement Equity Incentive Plan, aligning with the Nasdaq Listing Rule 5635(c)(4), which allows such grants as an inducement for new hires.

These RSUs are structured to vest over time, with 25% of the shares becoming eligible on the first anniversary of the vesting commencement date, followed by quarterly vesting of 1/16th of the shares until fully vested. The continued employment of the recipients through the vesting dates is a pivotal condition for these awards, ensuring alignment with Recursion’s long-term goals and performance metrics.

Recursion’s mission is centered around utilizing advanced technology to decode biology and significantly enhance healthcare outcomes. The company operates on the Recursion OS, a platform that generates an extensive biological and chemical dataset through extensive experimentation and sophisticated machine-learning algorithms. With the capability to execute millions of experiments weekly and operate one of the world’s most powerful supercomputers, Recursion aims to remove biases in biological research and foster advancements in medicine.

Headquartered in Salt Lake City, Recursion is a key player in the life sciences sector, also having a presence in Montréal, New York, London, and Oxford. This recent grant reflects Recursion's commitment to building a robust talent pool to achieve its ambitious goals in biology and medicine. For further information, visit www.recursion.com or connect via social media.

Recursion (NASDAQ: RXRX) has recently made headlines with its grant of inducement restricted stock unit (RSU) awards, totaling 820,431 shares as approved by its Compensation Committee. This strategic move underscores the company's commitment to building a strong workforce by attracting and retaining top talent, essential for its growth trajectory in the competitive TechBio sector.

Under the Nasdaq Listing Rule 5635(c)(4), these RSU awards are a pivotal incentive, allowing Recursion to bolster its team while ensuring that employees are aligned with the company’s long-term objectives. The vesting structure—25% after one year and the remainder quarterly thereafter—encourages employee retention and commitment to the company's mission: decoding biology to revolutionize medicine.

From an investor's perspective, this move indicates that Recursion is focused not only on its immediate operational goals but also on cultivating a sustainable workforce capable of leveraging its extensive biological and chemical datasets. The company's use of sophisticated machine-learning algorithms to navigate and analyze massive datasets positions it at the forefront of innovation, potentially translating into substantial future revenue streams as its discoveries progress through clinical trials.

Investors should monitor Recursion's progress through its 2024 Plan, as the successful integration of these new employees into its operations could catalyze meaningful developments. Additionally, the broader impact of enhancing its scientific and technical capabilities may improve investor sentiment and market performance.

As Recursion continues to advance its unique technological platform and expand its research capabilities, potential investors should approach with cautious optimism, capitalizing on any dips to acquire shares of this pioneering company. Given its strategic focus and innovative prowess, RXRX may represent a compelling investment opportunity in the burgeoning TechBio landscape.